Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12644-12655

  Bankwitz, Dorothea ^a   Vieyres, Gabrielle ^a   Hueging, Kathrin ^a   Bitzegeio, Julia ^a,c   Doepke, Mandy ^a   Chhatwal, Patrick ^a   Haid, Sibylle ^a   Catanese, Maria Teresa ^b,c   Zeisel, Mirjam B ^d,e   Nicosia, Alfredo ^f,g   Baumert, Thomas F ^d,e   Kaderali, Lars ^h   Pietschmann, Thomas ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROCKEFELLER UNIVERSITY   (United States)

^d INSERM   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CD81 ANTIGEN; CLAUDIN 1; LIPOPROTEIN; OCCLUDIN; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN 2; CD81 PROTEIN, HUMAN; CLDN1 PROTEIN, HUMAN; HVR1 PROTEIN, HEPATITIS C VIRUS; OCLN PROTEIN, HUMAN; PROTEIN BINDING; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B; VIRUS PROTEIN;

ARTICLE; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; GENE DELETION; GENE STRUCTURE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPERVARIABLE REGION 1; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRION; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENE; CELL LINE; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; LIVER CELL; METABOLISM; PHYSIOLOGY; PROTEIN ANALYSIS; VIROLOGY;

ANTIGENS, CD81; CELL LINE; CLAUDIN-1; GENE DELETION; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; LIPOPROTEINS; OCCLUDIN; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; SCAVENGER RECEPTORS, CLASS B; VIRAL PROTEINS; VIRUS INTERNALIZATION;

EID: 84907971360     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01145-14     Document Type: Article

References (56)

1. Lindenbach BD, Thiel HJ, Rice CM. 2007. Flaviviridae: the viruses and their replication, p 1101-1152. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Brown RS. 2005. Hepatitis C and liver transplantation. Nature 436:973-978 http://dx.doi.org/10.1038/nature04083.
3. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. http://dx.doi.org/10.1002/hep.20819.
4. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K. 1993. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitisCvirus. J. Virol. 67:3923-3930.
5. Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M, Shimotohno K. 1994. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J. Virol. 68:4776-4784.
6. Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, Tanaka T, Munekata E, Muchmore EE, Peterson DA, Mishiro S. 1993. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 195:297-301. http://dx.doi.org/10.1006/viro.1993.1378.
7. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. U. S. A. 89:3468-3472. http://dx.doi.org/10.1073/pnas.89.8.3468.
8. Kumar U, Monjardino J, Thomas HC. 1994. Hypervariable region of hepatitisCvirus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106:1072-1075.
9. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM. 2001. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 75:5703-5710. http://dx.doi.org/10.1128 /JVI.75.12.5703-5710.2001.
10. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pecheur EI, Pietschmann T. 2010. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84:5751-5763. http://dx.doi.org/10.1128/JVI.02200-09.
11. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. 2011. Hypervariable region 1 differentially impacts viability of hepatitisCvirus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 85:2224-2234. http://dx.doi.org/10.1128 /JVI.01594-10.
12. Chang KS, Jiang J, Cai Z, Luo G. 2007. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81:13783-13793. http://dx.doi.org/10.1128/JVI.01091-07.
13. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 104:5848-5853. http://dx.doi.org/10.1073/pnas.0700760104.
14. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. 2008. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 82:2120-2129. http://dx.doi.org/10.1128/JVI.02053-07.
15. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. 2013. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses 5:1292-1324. http://dx.doi.org/10.3390/v5051292.
16. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. 2011. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J. Biol. Chem. 286:3018-3032. http://dx.doi.org/10.1074/jbc.M110.175018.
17. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Terce F, Duverlie G, Rouille Y, Dubuisson J. 2012. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55:998-1007. http://dx.doi.org/10.1002/hep.25501.
18. Sainz B, Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18:281-285. http://dx.doi.org/10.1038/nm.2581.
19. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF. 2007. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46:1722-1731. http://dx.doi.org/10.1002/hep.21994.
20. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. 2007. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J. Virol. 81:8063-8071. http://dx.doi.org/10.1128/JVI.00193-07.
21. Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, Schwarz A, Moreau M, Owen JS, Leroux-Roels G, Balfe P, McKeating JA. 2007. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J. Virol. 81:3162-3169. http://dx.doi.org/10.1128/JVI.02356-06.
22. Dorner M, Rice CM, Ploss A. 2013. Study of hepatitis C virus entry in genetically humanized mice. Methods 59:249-257. http://dx.doi.org/10.1016/j.ymeth.2012.05.010.
23. Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. 2012. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J. Biol. Chem. 287:31242-31257. http://dx.doi.org/10.1074/jbc.M112.365924.
24. Maillard P, Huby T, Andreo U, Moreau M, Chapman J, Budkowska A. 2006 The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/ClaI is mediated by ApoB-containing lipoproteins. FASEB J. 20:735-737. http://dx.doi.org/10.1096/fj.05-4728fje.
25. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. http://dx.doi.org/10.1038/nature05654.
26. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. http://dx.doi.org/10.1038 /nature07684.
27. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941. http://dx.doi.org/10.1126/science.282.5390.938.
28. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006 Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413. http://dx.doi.org/10.1073/pnas.0504877103.
29. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. 2006. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80:5308-5320. http://dx.doi.org/10.1128/JVI.02460-05.
30. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
31. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. 2010. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 84:34-43. http://dx.doi.org/10.1128 /JVI.02199-08.
32. Ciesek S, Westhaus S, Wicht M, Wappler I, Henschen S, Sarrazin C, Hamdi N, Abdelaziz AI, Strassburg CP, Wedemeyer H, Manns MP, Pietschmann T, von Hahn T. 2011. Impact of intra-and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles. J. Virol. 85:7613-7621. http://dx.doi.org/10.1128/JVI.00212-11.
33. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF. 2010. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139:953-964. http://dx.doi.org/10.1053/j.gastro.2010.05.073.
34. Zahid MN, Turek M, Xiao F, Thi VL, Guerin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB. 2013. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57:492-504. http: //dx.doi.org/10.1002/hep.26097.
35. Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. 2011. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol. 54:48-55. http://dx.doi.org/10.1016/j.jhep.2010.06.024.
36. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. http://dx.doi.org/10.1038/nm1268.
37. Vieyres G, Pietschmann T. 2013. Entry and replication of recombinant hepatitis C viruses in cell culture. Methods 59:233-248. http://dx.doi.org /10.1016/j.ymeth.2012.09.005.
38. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH. 2001 Functional analysis of hepatitis C virus E2 glycoproteins and viruslike particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82:1877-1883.
39. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. 2012. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 55:364-372. http://dx.doi.org/10.1002 /hep.24692.
40. Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. 2012. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J. Hepatol. 57:17-23. http://dx.doi.org/10.1016/j.jhep.2012.02.018.
41. Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, Tall AR. 2009. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb. Vasc. Biol. 29:2054-2060. http://dx.doi.org/10.1161/ATVBAHA.109.191320.
42. Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, Pezzanera M, Ercole BB, McKeating J, Yagnik A, Lahm A, Tramontano A, Cortese R, Nicosia A. 2003. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 77:1856-1867. http://dx.doi.org/10.1128/JVI.77.3.1856-1867.2003.
43. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:41624-41630. http: //dx.doi.org/10.1074/jbc.M305289200.
44. Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 82:3197-3201 http://dx.doi.org/10.1073/pnas.82.10.3197.
45. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1999. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262:250-263. http://dx.doi.org/10.1006/viro.1999.9889.
46. Owen DM, Huang H, Ye J, Gale M, Jr. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with lowdensity lipoprotein receptor. Virology 394:99-108. http://dx.doi.org/10.1016/j.virol.2009.08.037.
47. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. 2012. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J. Virol. 86:7256-7267. http://dx.doi.org/10.1128/JVI.07222-11.
48. Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, Haid S, Gentzsch J, Kaderali L, Bartenschlager R, Pietschmann T. 2012. MAPkinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog. 8:e1002829. http://dx.doi.org/10.1371/journal.ppat.1002829.
49. Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J. 2014. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. J. Virol. 88: 1725-1739. http://dx.doi.org/10.1128/JVI.02017-13.
50. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. 1993. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268:10160-10167.
51. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278:41003-41012 http://dx.doi.org/10.1074/jbc.M302267200.
52. Jiang J, Wu X, Tang H, Luo G. 2013. Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors. PLoS One 8:e67982. http://dx.doi.org/10.1371/journal.pone.0067982.
53. Anggakusuma, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E. 2014. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 63:1137-1149. http://dx.doi.org/10.1136/gutjnl-2012-304299.
54. Narayanaswami V, Ryan RO. 2000. Molecular basis of exchangeable apolipoprotein function. Biochim. Biophys. Acta 1483:15-36. http://dx.doi.org/10.1016/S1388-1981(99)00176-6.
55. Spearman C. 1908. The method of "right and wrong cases" ("constant stimuli") without Gauss' s formulae. Br. J. Psychol. 2:227-242.
56. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-487.